EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Embracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial

Andreia Morais iD, Joseph J Locascio iD, Lauren H Sansing iD, Jessica Lamb iD, Karisma Nagarkatti iD, Takahiko Imai iD, Klaus van Leyen iD, Jaroslaw Aronowski iD, James I Koenig iD, Francesca Bosetti iD, Patrick Lyden iD, Cenk Ayata iD und 1 weitere

Stroke · 2023-02 · 54 (2) · 620-631

DOI: 10.1161/strokeaha.122.040638 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Stroke, 2023-02. Verfasst von Andreia Morais und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Harvard Medical School, Massachusetts General Hospital, Charlestown (A.M., T.I., K.v.L.). Hauptthemen laut MEDLINE: Stroke, Ischemic Attack, Transient. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIBIB NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Stroke Preclinical Assessment Network (SPAN) is a multicenter preclinical trial platform using rodent models of transient focal cerebral ischemia to address translational failure in experimental stroke. In addition to centralized randomization and blinding and large samples, SPAN aimed to introduce heterogeneity to simulate the heterogeneity embodied in clinical trials for robust conclusions. Here, we report the heterogeneity introduced by allowing the 6 SPAN laboratories to vary most of the biological and experimental model variables and the impact of this heterogeneity on middle cerebral artery occlusion (MCAo) performance. We included the modified intention-to-treat population of the control mouse cohort of the first SPAN trial (n=421) and examined the biological and procedural independent variables and their covariance. We then determined their impact on the dependent variables cerebral blood flow drop during MCAo, time to achieve MCAo, and total anesthesia duration using multivariable analyses. We found heterogeneity in biological and procedural independent variables introduced mainly by the site. Consequently, all dependent variables also showed heterogeneity among the sites. Multivariable analyses with the site as a random effect variable revealed filament choice as an independent predictor of cerebral blood flow drop after MCAo. Comorbidity, sex, use of laser Doppler flow to monitor cerebral blood flow, days after trial onset, and maintaining anesthesia throughout the MCAo emerged as independent predictors of time to MCAo. Total anesthesia duration was predicted by most independent variables. We present with high granularity the heterogeneity introduced by the biological and model selections by the testing sites in the first trial of cerebroprotection in rodent transient filament MCAo by SPAN. Rather than trying to homogenize all variables across all sites, we embraced the heterogeneity to better approximate clinical trials. Awareness of the heterogeneity, its sources, and how it impacts the study performance may further improve the study design and statistical modeling for future multicenter preclinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StrokeIschemic Attack, TransientMiceAnimalsDisease Models, AnimalInfarction, Middle Cerebral ArteryResearch DesignCerebrovascular CirculationMulticenter Studies as Topic

Stichwörter der Autor:innen

cerebrovascular circulationinfarctionischemiamicerodentiastroke

Autor:innen und Institutionen

  • Department of Radiology, Harvard Medical School, Massachusetts General Hospital, Charlestown (A.M., T.I., K.v.L.).
  • Department of Biostatistics, Harvard Medical School, Massachusetts General Hospital, Boston (J.J.L.).
  • Department of Neurology and Department of Immunobiology, Yale University School of Medicine, New Haven, CT (L.H.S).
  • Department of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Los Angeles, CA (J.L., K.N., P.L.).
  • Department of Neurology, McGovern Medical School, University of Texas HSC, Houston (J.A.).
  • National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD (J.I.K., F.B.).

ORCID-Profile: Andreia Morais, Joseph J Locascio, Lauren H Sansing, Jessica Lamb, Karisma Nagarkatti, Takahiko Imai, Klaus van Leyen, Jaroslaw Aronowski, James I Koenig, Francesca Bosetti, Patrick Lyden, Cenk Ayata

Förderung

  • NINDS NIH HHS
  • NIBIB NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Morais, A., Locascio, J. J., Sansing, L. H., Lamb, J., Nagarkatti, K., Imai, T., van Leyen, K., Aronowski, J., Koenig, J. I., Bosetti, F., Lyden, P., Ayata, C., & SPAN Investigators (2023). Embracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial. Stroke, 54(2), 620-631. https://doi.org/10.1161/strokeaha.122.040638

Vancouver

Morais A, Locascio JJ, Sansing LH, Lamb J, Nagarkatti K, Imai T, et al. Embracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial. Stroke. 2023;54(2):620-631. doi:10.1161/strokeaha.122.040638

BibTeX
@article{Morais2023,
  author = {Morais, Andreia and Locascio, Joseph J and Sansing, Lauren H and Lamb, Jessica and Nagarkatti, Karisma and Imai, Takahiko and van Leyen, Klaus and Aronowski, Jaroslaw and Koenig, James I and Bosetti, Francesca and Lyden, Patrick and Ayata, Cenk and SPAN Investigators, SPAN Investigators},
  title = {Embracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial},
  journal = {Stroke},
  year = {2023},
  volume = {54},
  number = {2},
  pages = {620--631},
  doi = {10.1161/strokeaha.122.040638}
}
Kostenlos starten →